Biora Therapeutics News: Latest Updates on the Private BioJet Developer
Biora Therapeutics is making big moves in biotech. It focuses on something exciting, smart drug delivery. The company uses tiny tech called BioJet™ to send medicine exactly where it’s needed in our bodies. That means fewer side effects and better results.
Many biotech firms are trying to improve how we take medicine. But Biora stands out. Its devices can target the digestive system, which is hard to reach. That could change the way we treat diseases like Crohn’s or ulcerative colitis.
We’ve seen a lot of news lately. Some updates are about clinical trials. Others are about funding or business changes. If you’ve been tracking BIOR stock, you’ve likely noticed shifts in price too.
Let’s find out all the latest updates. We’ll talk about the BioJet platform, Biora’s future plans, and what it means for investors.
Company Overview
Biora Therapeutics started in 2010 as Progenity, Inc. It is based in San Diego, California. In 2022, it changed its name to Biora to show its new focus on drug delivery systems.
At first, Biora was a public company. But in December 2024, it filed for Chapter 11 bankruptcy. It also began selling parts of the business to get money and grow its products.
Biora’s goal is to change how medicine is given. It builds smart pill systems that help drugs work better and improve life for people with long-term illnesses.
The BioJet™ Platform
The BioJet™ platform is a smart pill that gives medicine straight into the small intestine. It works without needles. Instead, it uses a liquid jet to push the drug into the body.
This system can give large doses over 50 milligrams without changing the drug too much. That helps people who need strong or big doses of medicine.
BioJet™ is better than shots or other old ways of taking drugs. It’s easier for patients and doesn’t hurt. This makes it a more comfortable and simple choice.
Latest Clinical or Research Updates
Biora’s trial for BT-600, a drug-device combo, showed good results. In Phase 1, the drug was safe and met all goals. This proved the NaviCap™ system can send medicine straight to the colon.
Biora is also working on the BioJet™ system in early lab stages. At a top biotech meeting, they shared news about a new, smaller BioJet™ capsule. It can carry the biggest dose of any pill that injects inside the body.
These steps show Biora’s strong focus on making drug delivery better and smarter.
Strategic Partnerships & Business Developments
In August 2024, Biora got $16 million from its current investors. This money helps the company keep going until it makes new drug deals. It supports work on BioJet™ and NaviCap™.
Biora also teamed up with research groups. They are working together to make the BioJet™ platform better and faster. These deals help Biora grow in the biotech world.
BIOR Stock Performance & Market Response
Biora’s stock, now trading as BIORQ, has gone up and down a lot. In the past year, the price moved between $0.08 and $7.90. This shows big market changes and investor worries.
The company filed for Chapter 11 bankruptcy. That made investors more careful. But the new funding and progress in drug delivery tools give some hope.
Investors should watch Biora closely. Its smart tech and future plans could help its value grow later.
Future Outlook
Looking ahead, Biora plans to grow its BioJet™ and NaviCap™ platforms. It will keep testing them in trials and work with new partners. The goal is to get approvals and help more patients.
There is a big need for easy, non-invasive treatments. Biora’s tools could meet that need. If these products succeed, Biora could become a top name in biotech.
Final Thoughts
Biora Therapeutics is working on new ways to give medicine. Even with recent problems, the company keeps moving forward. Its BioJet™ and NaviCap™ tools are made to help patients feel better.
Biora is teaming up with others and doing more research. These steps could lead to big changes in how we treat long-term illnesses.
People who invest in health companies should watch Biora. Its new ideas may help shape the future of medicine.
Frequently Asked Questions (FAQs)
Biora Therapeutics’ stock is falling. The company has money problems. It filed for bankruptcy in December 2024. Investors are worried. They are unsure about the company’s future. That caused the drop.
Biora Therapeutics is headquartered in San Diego, California. The company focuses on developing innovative drug delivery systems to improve patient outcomes.
Disclaimer:
This content is for informational purposes only and not financial advice. Always conduct your research.